Dave Ricks, CEO of Eli Lilly | The All-In Interview

David Friedberg engages in a conversation with Eli Lilly CEO Dave Ricks, exploring the global obesity epidemic and the discovery of GLP-1s. They discuss the effects of GLP-1s on various human functions and delve into the commercial aspects of drug discovery, including pricing strategies. The episode addresses criticism and research surrounding GLP-1 dependency, as well as the company's stock performance and political pressures tied to successful drugs. Dave Ricks shares insights on Eli Lilly's diverse drug portfolio beyond GLP-1s and the scientific advancements that excite him. The episode concludes with a discussion on scaling and influencing culture in a company with over a century of history.